Better Therapeutics (NASDAQ: BTTX) appointed Deepti Sodhi Jaggi, PharmD, as its new Chief Strategy Officer. With extensive experience in healthcare technology, including roles at Astellas Pharmaceuticals and Johnson & Johnson, Dr. Jaggi aims to leverage her expertise to enhance the company's efforts in treating cardiometabolic diseases. CEO Kevin Appelbaum expressed confidence in her ability to drive innovation within the organization. Better Therapeutics develops digital therapeutics that integrate cognitive behavioral therapy to address conditions like type 2 diabetes and heart disease.
Better Therapeutics (NASDAQ: BTTX) announced the completion of patient enrollment in a pivotal study for BT-001, a prescription digital therapeutic aimed at treating type 2 diabetes. The study enrolled 662 patients across several states, exceeding its target. Positive results could lead to FDA marketing authorization. The company is also conducting a real-world evidence study to evaluate BT-001's long-term effectiveness. The digital therapy aims to improve treatment outcomes by addressing the psychological factors influencing diet and lifestyle, potentially lowering healthcare costs.
Better Therapeutics, Inc. (NASDAQ: BTTX) announces the appointment of Thiago Licias de Oliveira as Chief People Officer, a new role focused on developing a comprehensive people strategy amidst expected growth. Oliveira, formerly with Johnson & Johnson Medical Devices, aims to enhance team structure and retention. CEO Kevin Appelbaum emphasized the importance of leadership in attracting top talent. Better Therapeutics specializes in prescription digital therapeutics designed to treat cardiometabolic diseases through cognitive behavioral therapy, potentially lowering healthcare costs and improving patient outcomes.
Better Therapeutics has announced the start of a real-world evidence study to assess the effectiveness of BT-001, a prescription digital therapeutic for treating type 2 diabetes. This study, conducted in partnership with Mass General Brigham and others, will involve around 750 patients and last at least 18 months. It will measure the impact of BT-001 on health metrics and healthcare costs. Positive results could support FDA marketing approval for BT-001 as a prescribed digital solution, with potential reimbursement.
Better Therapeutics has finalized its business combination with Mountain Crest Acquisition Corp II, with trading set to begin on Nasdaq under ticker symbol BTTX on October 29, 2021. Shareholders approved the merger, which generated approximately $70 million in gross proceeds. The funds will advance Better Therapeutics' lead product, BT-001, for type 2 diabetes treatment, and support its broader pipeline in cardiometabolic conditions. The leadership team, including CEO Kevin Appelbaum and CMO Mark Berman, aims to enhance digital therapeutics accessibility.